Sign in to view content

Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting

Matthew Starr, MD

Video
Published 2021

Related

Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch
Estephania Feria, MD
On Demand Cases, Courses, and Papers
2019
Impact of Initial Monthly Doses of Aflibercept on Visual Outcomes in Eyes With Diabetic Macular Edema in Routine Clinical Practice in the US
Ferhina S Ali, MD, MPH
Annual Meeting Talks
2023
Modeling the Effect of Longer-Acting Drugs and Reimbursement Changes
Robert A Diamond, BBA
Updates from the Field
2022

Category: Diabetic Retinopathy

See more